395 related articles for article (PubMed ID: 27189323)
1. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
Nakamura M; Ojima T; Katsuda M; Hayata K; Kitadani J; Nakamori M; Yamaue H
Oncology; 2021; 99(1):57-61. PubMed ID: 32877909
[TBL] [Abstract][Full Text] [Related]
5. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
Kawamoto Y; Komatsu Y; Yuki S; Sawada K; Muranaka T; Harada K; Nakatsumi H; Fukushima H; Ishiguro A; Dazai M; Hatanaka K; Nakamura M; Iwanaga I; Uebayashi M; Sogabe S; Kobayashi Y; Miyagishima T; Ono K; Sakamoto N; Sakata Y
BMC Cancer; 2017 Dec; 17(1):837. PubMed ID: 29221445
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
Fujii M; Tomita K; Nishijima W; Tsukuda M; Hasegawa Y; Ishitoya J; Yamane H; Homma A; Tomita T
Jpn J Clin Oncol; 2010 Mar; 40(3):214-21. PubMed ID: 19934112
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
11. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
Iwase H; Shimada M; Tsuzuki T; Ina K; Sugihara M; Haruta J; Shinoda M; Kumada T; Goto H
Oncology; 2011; 80(1-2):76-83. PubMed ID: 21659786
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Moehler M; Mahlberg R; Heinemann V; Obermannová R; Kubala E; Melichar B; Weinmann A; Scigalla P; Tesařová M; Janda P; Hédouin-Biville F; Mansoor W
Gastric Cancer; 2017 Mar; 20(2):358-367. PubMed ID: 27255289
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
Koizumi W; Takiuchi H; Yamada Y; Boku N; Fuse N; Muro K; Komatsu Y; Tsuburaya A
Ann Oncol; 2010 May; 21(5):1001-5. PubMed ID: 19875759
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
Ishigami H; Kitayama J; Otani K; Kamei T; Soma D; Miyato H; Yamashita H; Hidemura A; Kaisaki S; Nagawa H
Oncology; 2009; 76(5):311-4. PubMed ID: 19299904
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Fujitani K; Narahara H; Takiuchi H; Tsujinaka T; Satomi E; Gotoh M; Hirao M; Furukawa H; Taguchi T
Oncology; 2005; 69(5):414-20. PubMed ID: 16319513
[TBL] [Abstract][Full Text] [Related]
17. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.
Mochiki E; Ohno T; Kamiyama Y; Aihara R; Haga N; Ojima H; Nakamura J; Ohsawa H; Nakabayashi T; Takeuchi K; Asao T; Kuwano H;
Br J Cancer; 2006 Dec; 95(12):1642-7. PubMed ID: 17133268
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.
Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545
[TBL] [Abstract][Full Text] [Related]
20. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
